DEBIOS Dx

DEBIOS Dx una de les 20 startups ‘deeptech’ seleccionades per participar a l’Startup Capital d’ACCIÓ El programa #StartupCapital ofereix ajuts directes de fins a 100.000 euros a empreses emergents de base tecnològica amb un alt potencial transformador per ajudar-les a finançar les primeres etapes dels seus projectes, les més crítiques.   El programa no només ofereix finançament, sinó que proporciona a les startups mentoratge, un ‘bootcamp’ formatiu, oportunitats de ‘networking’, incloent-hi una sessió exclusivament dedicada a conèixer inversors i fons d’inversió especialitzats Agraïts ACCIÓ per la vostra confiança !!

The International Society of Nephrology (ISN) is calling on the global community to take action on kidney health at the 79th United Nations General Assembly. Kidney disease is a growing public health crisis, often progressing silently until it's too late. To address this, the ISN has launched a global petition urging UN Member States to request that the WHO prioritize kidney health. By signing this petition, we can push for bold measures and policies that promote early detection and prevention of kidney disease—critical steps that align with DEBIOS Dx’s mission to revolutionize diagnostics with non-invasive solutions. Join the movement to make kidney health a global priority. Sign here 👉 https://lnkd.in/d79Xerez #DebiosDX #Nephrology #RenalFibrosis #KidneyCare #GlobalHealth #UNGA #Prevention #EarlyDetection

Another huge impulse to our project. At DEBIOS Dx we've been awarded with the "StartUp Capital" grant from ACCIÓ The budget received gives us fuel to push the project, but it is much more than that. - It means the validation of our strategy (yes, strategy matters) - It means team recognition after S1 hard work (implementation is key) - It means we'll be able to securely initiate our clinical trial in liquid biopsy for #CKD - It means our team will start to grow, being able to hire top talented people to perform key activities. - It means business development, IP strengthening, etc. ...means a lot. Hopefully more traction for our open seed round. We've been ranked the second project on best valuation from an extensive list of amazing startups and spinoffs. Taking-off. Keep pushing. Keep following us. Do you want to become early-stage investor? Just drop us a message to know more at info@debiosdx.com #RenalCareMatters

🌟 New hope for treating renal and cardiac fibrosis! 🌟 Exciting research published in ACS Pharmacology & Translational Science highlights the potential of sodium astragalosidate (SA) as a promising oral therapy for fibrosis. Traditional Chinese medicine has long utilized Radix Astragali for its anti-fibrotic properties, and now, modern science is unlocking its potential through optimized formulations. 📢 Key Findings: 1️⃣ Cardiac Fibrosis: In rat models, SA significantly reduced collagen accumulation and inflammation markers (TNF-α, IL-1β, and IL-6), demonstrating its potential to ameliorate cardiac fibrosis. 2️⃣ Renal Fibrosis: In diabetic mice, long-term oral administration of SA improved lipid metabolism and renal function, evidenced by decreased blood urea nitrogen and improved kidney histology. SA effectively suppressed the TGF-β1/Smads signaling pathway, crucial in fibrotic progression. 📍 Significance: These findings are a step forward in developing non-invasive, long-term treatments for fibrosis. At DEBIOS Dx, we are dedicated to advancing non-invasive renal fibrosis diagnostics, and this research supports our mission by highlighting the potential of innovative therapies like SA to improve patient outcomes. Stay tuned for more updates on groundbreaking research and advancements in kidney care! #DebiosDX #Nephrology #RenalFibrosis #KidneyCare #InnovativeTherapy #FibrosisResearch #NonInvasiveDiagnostics #TraditionalChineseMedicine #CardiacHealth #DiabetesCare Read the full study here 👇 https://lnkd.in/dhH-ww5y